1,2-二甲基-4-硝基-1H-苯并咪唑 | 73902-41-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1,2-二甲基-4-硝基-1H-苯并咪唑
• 英文名称: 1,2-dimethyl-4-nitro-1H-benzoimidazole
• 英文别名: 1,2-Dimethyl-4-nitro-1H-benzoimidazole；1,2-Dimethyl-4-nitrobenzimidazol；1,2-dimethyl-4-nitrobenzimidazole
• CAS: 73902-41-7
• 化学式: C₉H₉N₃O₂
• 分子量: 191.189
• InChiKey: XBSMDKNFRAVRCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  63.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,2-二甲基-4-硝基-1H-苯并咪唑 、 (4-aminobenzimidazol-2-yl)methanol 生成 1,2-二甲基-1H-苯并咪唑-4-胺
  参考文献：
  名称：

  TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

  摘要：

  本发明涉及三轮车I及其治疗和预防用途，其中变量C1、C2、Z1、Z2、Q、J、R1和R3在规范中定义。治疗和/或预防的疾病包括类风湿性关节炎。

  公开号：

  US20120129811A1
• 作为产物：
  描述：

  2-甲基苯并咪唑 在 氢氧化钾 、 硫酸 、 硝酸 作用下， 以 水 、 丙酮 为溶剂， 反应 3.0h， 生成 1,2-二甲基-4-硝基-1H-苯并咪唑
  参考文献：
  名称：

  Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit

  摘要：

  Here we report on novel quinoxalines as highly potent and selective inhibitors of the type III receptor tyrosine kinases PDGFR, FLT3, and KIT. These compounds, tricyclic quinoxalines, were generated in order to improve bioavailability over the highly hydrophobic bicyclic quinoxalines. Four of the highly active compounds were characterized in detail and are shown to inhibit PDGFR kinase activity of the isolated receptor as well as in intact cells in the sub-micromolar concentration range. We show that the most active inhibitor (compound 13, AGL 2043) is similar to 15-20 times more potent than its isomer (compound 14, AGL 2044). We therefore compared the three dimensional structures of the two compounds by X-ray crystallography. These compounds are also highly effective in blocking the kinase activity of FLT3, KIT, and the oncogenic protein Tel-PDGFR in intact cells. These compounds are potent inhibitors of the proliferation of pig heart smooth muscle cells. They fully arrest the growth of these cells and the effect is fully reversible. The chemical, biochemical and cellular properties of these compounds as well as the solubility properties make them suitable for development as anti-restenosis and anti-cancer agents. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00048-8

文献信息

• [EN] BENZIMIDAZOLE DERIVATIVES AND THEIR USE IN THE PREVENTION AND/OR THE TREATMENT OF BONE DISEASES<br/>[FR] DERIVES BENZIMIDAZOLIQUES, ET LEUR UTILISATION DANS LA PREVENTION ET LE TRAITEMENT DE MALADIES OSSEUSES
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：WO1997010219A1

  公开（公告）日：1997-03-20

  (EN) The present invention relates to a new heterocyclic compound of formula (I), wherein R1 is acyl, lower alkenyl or lower alkyl optionally substituted with aryl, a heterocyclic group, etc., R2 is hydrogen, lower alkyl, hydroxy(lower)alkyl, halo(lower)alkyl, etc., R3 is hydrogen or halogen, R4 is a heterocyclic group or aryl, each of which may be substituted with suitable substituent(s), and A is (a) or (b), (wherein R9 and R10 are each hydrogen, lower alkyl or substituted lower alkyl), and pharmaceutically acceptable salts thereof which are the inhibitors of bone resorption and bone metabolism, to processes for preparation thereof, to a pharmaceutical composition comprising the same and to a method for the treatment of diseases caused by abnormal bone metabolism in human being or an animal.(FR) L'invention porte sur un composé hétérocyclique représenté par la formule (I) ci-après, où: R1 est acyle, alcényle inférieur ou alkyle inférieur facultativement substitué par aryle, un groupe hétérocyclique, etc.; R2 est hydrogène, alkyle inférieur, alkyle (inférieur) hydroxy, alkyle (inférieur) halo, etc.; R3 est hydrogène ou halogène; R4 est un groupe hétérocyclique ou aryle, chacun d'entre eux pouvant être facultativement substitué par un ou plusieurs substituants appropriés; et A est représenté par (a) ou (b) (où R9 et R10 sont chacun hydrogène, alkyle inférieur ou alkyle inférieur substitué). Cette invention concerne également: les sels pharmaceutiquement acceptables de ce composé qui sont inhibiteurs de résorption osseuse et du métabolisme osseux; les procédés permettant de réaliser la préparation de ce composé; une composition pharmaceutique comprenant ce composé; et une méthode de traitement des maladies causées par un métabolisme osseux anormal chez l'homme ou l'animal.

  本发明涉及一种新的杂环化合物，其化学式为(I)，其中R1为酰基、较低的烯基或较低的烷基，可选择地被芳基、杂环基等取代，R2为氢、较低的烷基、羟基(较低)烷基、卤代(较低)烷基等，R3为氢或卤素，R4为杂环基或芳基，每个基团可以被适当的取代基所取代，A为(a)或(b)，其中R9和R10分别为氢、较低的烷基或取代的较低烷基。本发明还涉及该化合物的药学上可接受盐，其为骨吸收和骨代谢的抑制剂，以及制备该化合物的方法、包含该化合物的制药组合物以及治疗人类或动物骨代谢异常引起的疾病的方法。
• REDDY V. M.; REDDY K. K., INDIAN J. CHEM., 1979, B 17, NO 4, 357-359
  作者：REDDY V. M.、 REDDY K. K.

  DOI：——

  日期：——
• BENZIMIDAZOLE DERIVATIVES AND THEIR USE IN THE PREVENTION AND/OR THE TREATMENT OF BONE DISEASES
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0863881A1

  公开（公告）日：1998-09-16
• [EN] TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION<br/>[FR] INHIBITEURS TRICYCLIQUES D'ACTIVATION DE MÉTALLOPROTÉINASES PROMATRICIELLES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2012068211A1

  公开（公告）日：2012-05-24

  This invention relates to tricycle I and its therapeutic and prophylactic uses, wherein the variables C1, C2, Z1, Z2, Q, J, R1, and R3 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.
• Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit
  作者：Aviv Gazit、Kevin Yee、Andrea Uecker、Frank-D Böhmer、Tobias Sjöblom、Arne Östman、Johannes Waltenberger、Gershon Golomb、Shmuel Banai、Michael C Heinrich、Alexander Levitzki

  DOI：10.1016/s0968-0896(03)00048-8

  日期：2003.5

  Here we report on novel quinoxalines as highly potent and selective inhibitors of the type III receptor tyrosine kinases PDGFR, FLT3, and KIT. These compounds, tricyclic quinoxalines, were generated in order to improve bioavailability over the highly hydrophobic bicyclic quinoxalines. Four of the highly active compounds were characterized in detail and are shown to inhibit PDGFR kinase activity of the isolated receptor as well as in intact cells in the sub-micromolar concentration range. We show that the most active inhibitor (compound 13, AGL 2043) is similar to 15-20 times more potent than its isomer (compound 14, AGL 2044). We therefore compared the three dimensional structures of the two compounds by X-ray crystallography. These compounds are also highly effective in blocking the kinase activity of FLT3, KIT, and the oncogenic protein Tel-PDGFR in intact cells. These compounds are potent inhibitors of the proliferation of pig heart smooth muscle cells. They fully arrest the growth of these cells and the effect is fully reversible. The chemical, biochemical and cellular properties of these compounds as well as the solubility properties make them suitable for development as anti-restenosis and anti-cancer agents. (C) 2003 Elsevier Science Ltd. All rights reserved.